- Home
- BCDA vs ALZN Comparison
BCDA vs ALZN Comparison
Compare BCDA & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- ALZN
- Stock Information
- Founded
- BCDA N/A
- ALZN 2016
- Country
- BCDA United States
- ALZN United States
- Employees
- BCDA N/A
- ALZN N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- BCDA Health Care
- ALZN Health Care
- Exchange
- BCDA Nasdaq
- ALZN Nasdaq
- Market Cap
- BCDA 7.9M
- ALZN 7.0M
- IPO Year
- BCDA N/A
- ALZN 2021
- Fundamental
- Price
- BCDA $1.85
- ALZN $1.36
- Analyst Decision
- BCDA Strong Buy
- ALZN Strong Buy
- Analyst Count
- BCDA 1
- ALZN 1
- Target Price
- BCDA $25.00
- ALZN $35.00
- AVG Volume (30 Days)
- BCDA 61.9K
- ALZN 123.2K
- Earning Date
- BCDA 11-13-2024
- ALZN 12-13-2024
- Dividend Yield
- BCDA N/A
- ALZN N/A
- EPS Growth
- BCDA N/A
- ALZN N/A
- EPS
- BCDA N/A
- ALZN N/A
- Revenue
- BCDA $71,000.00
- ALZN N/A
- Revenue This Year
- BCDA $6.92
- ALZN N/A
- Revenue Next Year
- BCDA N/A
- ALZN N/A
- P/E Ratio
- BCDA N/A
- ALZN N/A
- Revenue Growth
- BCDA N/A
- ALZN N/A
- 52 Week Low
- BCDA $1.84
- ALZN $1.31
- 52 Week High
- BCDA $12.00
- ALZN $19.20
- Technical
- Relative Strength Index (RSI)
- BCDA 29.98
- ALZN 32.37
- Support Level
- BCDA $2.21
- ALZN $1.43
- Resistance Level
- BCDA $2.47
- ALZN $1.59
- Average True Range (ATR)
- BCDA 0.16
- ALZN 0.10
- MACD
- BCDA -0.04
- ALZN -0.01
- Stochastic Oscillator
- BCDA 1.30
- ALZN 13.16
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.